23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American ...

23ME-01473, antibody targeting ULBP6: Data will be presented on the discovery and biology of ULBP6, and the potential to restore natural killer and T cell-mediated anti-tumor immunity by targeting ULBP6

Related Keywords

United States ,San Diego ,California ,American , ,Nasdaq ,Securities Exchange ,Exchange Commission ,Clinical Research ,Me Holding Co ,American Association For Cancer Research ,American Association ,Cancer Research ,Annual Meeting ,Cancer Genome Atlas ,Stage Monoclonal Antibody Targeting ,Investor Relations ,Drug Discovery ,New Targets ,Upper Level ,San Diego Convention ,Abstract Number ,Poster Section ,Board Number ,Securities Act ,Securities Exchange Act ,Annual Report ,Quarterly Reports ,Current Reports ,Relations Contact ,Region ,